News from trovagene, inc A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

May 13, 2015, 17:01 ET
A molecular diagnostics company with unique intellectual property around the discovery that DNA and RNA, present in urine, can be diagnostic of cancer and infectious disease.

Clinical Utility of Trovagene's Urine-Based Liquid Biopsy Platform to Be Highlighted at the American Society of Clinical Oncology Meeting

 Trovagene, Inc. (NASDAQ: TROV), a developer of cell-free molecular diagnostics, announced today that clinical data from four studies utilizing...

May 05, 2015, 16:01 ET
A molecular diagnostics company with unique intellectual property around the discovery that DNA and RNA, present in urine, can be diagnostic of cancer and infectious disease.

Trovagene, Inc. Announces First Quarter 2015 Financial Results

 Trovagene, Inc. (NASDAQ: TROV), a developer of cell-free molecular diagnostics, today reported its financial results for the three months...

May 04, 2015, 08:00 ET
A molecular diagnostics company with unique intellectual property around the discovery that DNA and RNA, present in urine, can be diagnostic of cancer and infectious disease

Cost Benefit Analysis of Trovagene's Precision Cancer Monitoring Solution to Be Presented at the Association for Value-Based Cancer Care in Washington, DC

 Trovagene, Inc., (NASDAQ: TROV) a developer of cell-free molecular diagnostics, announced today that Gary Gustavsen, Vice President, Health...

Apr 28, 2015, 08:00 ET
A molecular diagnostics company with unique intellectual property around the discovery that DNA and RNA, present in urine, can be diagnostic of cancer and infectious disease.

Trovagene Schedules Release of First Quarter 2015 Financial Results and Investor Conference Call

 Trovagene, Inc. (NASDAQ:  TROV), a developer of cell-free molecular diagnostics, announced today that it will report financial results...

Apr 23, 2015, 08:00 ET
A molecular diagnostics company with unique intellectual property around the discovery that DNA and RNA, present in urine, can be diagnostic of cancer and infectious disease

Trovagene's Urine-Based HPV Assay to Be Featured in Presentation at the 13th Annual Cervical Cancer Conference and HPV Consortium in Beijing

 Trovagene, Inc., (NASDAQ:  TROV) a developer of cell-free molecular diagnostics, announced today that study investigator, John Cuzick,...

Apr 20, 2015, 08:00 ET
A molecular diagnostics company with unique intellectual property around the discovery that DNA and RNA, present in urine, can be diagnostic of cancer and infectious disease.

Poster Presentations at 2015 AACR Annual Meeting to Highlight Clinical Utilities and Advantages of Trovagene's ctDNA Precision Cancer Monitoring Platform

 Trovagene, Inc., (NASDAQ:  TROV) a developer of cell-free molecular diagnostics, announced today that clinical and analytical data for...

Apr 17, 2015, 10:30 ET
A molecular diagnostics company with unique intellectual property around the discovery that DNA and RNA, present in urine, can be diagnostic of cancer and infectious disease.

Trovagene's Urinary ctDNA Assay Outperforms Tissue Biopsy in Clinical Study for the Detection of EGFR T790M Mutations in Metastatic Lung Cancer Patients

 Trovagene, Inc., (NASDAQ: TROV) a developer of cell-free molecular diagnostics, announced today that clinical data presented at the 2015...

Mar 18, 2015, 08:31 ET
A molecular diagnostics company with unique intellectual property around the discovery that DNA and RNA, present in urine, can be diagnostic of cancer and infectious disease.

Matthew Posard Joins Trovagene's Executive Management Team as Chief Commercial Officer

 Trovagene, Inc., (NASDAQ: TROV) a developer of cell-free molecular diagnostics, announced today that Matthew L. Posard has joined the...

Mar 12, 2015, 16:05 ET
A molecular diagnostics company with unique intellectual property around the discovery that DNA and RNA, present in urine, can be diagnostic of cancer and infectious disease.

Trovagene, Inc. Reports Fourth Quarter and Full Year 2014 Financial Results

 Trovagene, Inc. (NASDAQ: TROV), a developer of cell-free molecular diagnostics, today reported its financial results for the fourth...

Feb 26, 2015, 16:05 ET
A molecular diagnostics company with unique intellectual property around the discovery that DNA and RNA, present in urine, can be diagnostic of cancer and infectious disease.

Trovagene Schedules Release of Fourth Quarter and Year End 2014 Financial Results and Investor Conference Call

Trovagene, Inc. (NASDAQ: TROV), a developer of cell-free molecular diagnostics, announced today that it will report financial results for the...

Feb 11, 2015, 10:12 ET
A molecular diagnostics company with unique intellectual property around the discovery that DNA and RNA, present in urine, can be diagnostic of cancer and infectious disease.

Trovagene, Inc. Announces Closing of Public Offering of Common Stock

 Trovagene, Inc. (NASDAQ: TROV) today announced the closing of its previously announced underwritten public offering.  The Company sold...

Feb 10, 2015, 08:05 ET
A molecular diagnostics company with unique intellectual property around the discovery that DNA and RNA, present in urine, can be diagnostic of cancer and infectious disease.

Trovagene, Inc. to Present at Leerink Global Healthcare Conference

 Trovagene, Inc. (NASDAQ: TROV), a developer of cell-free molecular diagnostics, today announced that Chief Executive Officer...

Feb 09, 2015, 08:05 ET
A molecular diagnostics company with unique intellectual property around the discovery that DNA and RNA, present in urine, can be diagnostic of cancer and infectious disease.

Clinical Results Demonstrate High Sensitivity of Trovagene's Urine-Based HPV Assay for the Detection of High Risk HPV and Pre-Cancerous Cervical Lesions

 Trovagene, Inc., (NASDAQ:  TROV) a developer of cell-free molecular diagnostics, announced the presentation of clinical results from the...

Feb 06, 2015, 08:27 ET
A molecular diagnostics company with unique intellectual property around the discovery that DNA and RNA, present in urine, can be diagnostic of cancer and infectious disease.

Trovagene, Inc. Announces Pricing of Public Offering of Common Stock

Trovagene, Inc. (NASDAQ: TROV), a developer of cell-free molecular diagnostics, today announced the pricing of an underwritten public offering...

Feb 05, 2015, 16:09 ET
A molecular diagnostics company with unique intellectual property around the discovery that DNA and RNA, present in urine, can be diagnostic of cancer and infectious disease.

Trovagene, Inc. Announces Public Offering of Common Stock

 Trovagene, Inc. (NASDAQ: TROV), a developer of cell-free molecular diagnostics, today announced that it is offering to sell shares of its...

Jan 26, 2015, 08:35 ET
A molecular diagnostics company with unique intellectual property around the discovery that DNA and RNA, present in urine, can be diagnostic of cancer and infectious disease.

Trovagene's Chief Scientific Officer to Present Precision Cancer Monitoring (SM) Platform Overview at the Personalized Medicine World Conference

 Trovagene, Inc., (NASDAQ: TROV) a developer of cell-free molecular diagnostics, announced today that Chief Scientific Officer, Mark Erlander,...

Jan 21, 2015, 03:01 ET
A molecular diagnostics company with unique intellectual property around the discovery that DNA and RNA, present in urine, can be diagnostic of cancer and infectious disease.

Trovagene Expands Collaboration with Genomac to Demonstrate Clinical Utility in Lung and Colorectal Cancer Treatment Monitoring

Trovagene, Inc. (NASDAQ:  TROV), today announced it will expand the clinical collaboration with Genomac Research Institute in Prague, Czech...

Jan 20, 2015, 08:15 ET
A molecular diagnostics company with unique intellectual property around the discovery that DNA and RNA, present in urine, can be diagnostic of cancer and infectious disease.

Clinical Study Results Presented at the 2015 Gastrointestinal Cancer Symposium Support Utility of Trovagene's Precision Cancer Monitoring Platform in Colorectal and Pancreatic Cancer Patients

 Trovagene, Inc., (NASDAQ:  TROV) a developer of cell-free molecular diagnostics, announced the presentation of results from two clinical...

Jan 12, 2015, 08:35 ET
A molecular diagnostics company with unique intellectual property around the discovery that DNA and RNA, present in urine, can be diagnostic of cancer and infectious disease.

Trovagene Collaborates with UC San Diego Moores Cancer Center to Demonstrate Clinical Utility of Detecting and Monitoring EGFR Mutations in Lung Cancer Patients

 Trovagene, Inc. (NASDAQ:  TROV), today announced that it has entered into a clinical collaboration with University of California, San...

Jan 08, 2015, 08:00 ET
A molecular diagnostics company with unique intellectual property around the discovery that DNA and RNA, present in urine, can be diagnostic of cancer and infectious disease.

Trovagene and City of Hope Collaborate To Monitor EGFR Mutational Status in Lung Cancer Patients

 Trovagene, Inc. (NASDAQ:  TROV), today announced that it has entered into a clinical collaboration with City of Hope to conduct studies...